E-viri
Recenzirano
Odprti dostop
-
Reigadas, E.; Alcalá, L.; Marín, M.; Martin, A.; Muñoz, P.; Bouza, E.; Sánchez-Arroyo, Rafael J.; Azcona-Gutiérrez, José Manuel; García-García, Concepción; Fernández-Caso, Belén; García-Blanco, Alicia; Fernandez-Pittol, Mariana; Álvarez-Martínez, Míriam José; Orellana Miguel, M. Ángeles; Nuño, Enrique Muñoz; Álvarez-Paredes, Ledicia; Megías, Gregoria; Medrano, Ramiro López; Foz, Carlos Fuster; Leiva, José; Fernández-Alonso, Mirian; Vega, Silvia; Hernando, Susana; de Frutos, Mónica; Eiros, José María; Trujillo, Gloria; López, Joan; Molina de Diego, Araceli N.; López Hontangas, José Luis; Guerrero-Vadillo, María
Anaerobe, February 2020, 2020-Feb, 2020-02-00, 20200201, Letnik: 61Journal Article
Classification of patients according to their risk of poor outcomes in Clostridioides difficile infection (CDI) would enable implementation of costly new treatment options in a subset of patients at higher risk of poor outcome. In a previous study, we found that low toxin B amplification cycle thresholds (Ct) were independently associated with poor outcome CDI. Our objective was to perform a multicentre external validation of a PCR-toxin B Ct as a marker of poor outcome CDI. We carried out a multicentre study (14 hospitals) in which the characteristics and outcome of patients with CDI were evaluated. A subanalysis of the results of the amplification curve of real-time PCR gene toxin B (XpertTM C. difficile) was performed. A total of 223 patients were included. The median age was 73.0 years, 50.2% were female, and the median Charlson index was 3.0. The comparison of poor outcome and non–poor outcome CDI episodes revealed, respectively, the following results: median age (years), 77.0 vs 72.0 (p = 0.009); patients from nursing homes, 24.4% vs 10.8% (p = 0.039); median leukocytes (cells/μl), 10,740.0 vs 8795.0 (p = 0.026); and median PCR-toxin B Ct, 23.3 vs 25.4 (p = 0.004). Multivariate analysis showed that a PCR-toxin B Ct cut-off <23.5 was significantly and independently associated with poor outcome CDI (p = 0.002; OR, 3.371; 95%CI, 1.565–7.264). This variable correctly classified 68.5% of patients. The use of this microbiological marker could facilitate early selection of patients who are at higher risk of poor outcome and are more likely to benefit from newer and more costly therapeutic options. •Patients with poor outcome CDI presented lower PCR toxin B amplification Ct•When cut-off (<23.5Ct) was applied we found independent association with poor outcome•We successfully stratified nearly 70% of patients with poor outcome CDI
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.